Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…
Entries by arcticnovartis
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
arcticnovartis
Thu, 10/24/2024 – 07:19
Read more about Novartis ribociclib (Kisq…
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Fri, 10/18/2024 – 12:49
Read more about Novartis receives positive CHMP opinion for Kisqali® to help…
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Tue, 09/17/2024 – 19:04
Read more about FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- ea…
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis
Mon, 09/16/2024 – 10:19
Read more about Novartis Kisqali® shows deepening…
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
arcticnovartis
Wed, 08/28/2024 – 07:19
Read more about Novartis twice-yearly* Le…
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis
Thu, 08/08/2024 – 01:34
Read more about Novartis receiv…
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
arcticnovartis
Mon, 07/29/2024 – 18:04
Read more about Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly …